C-ATJCRegerna Therapeutics
RNA-binding proteins, AUF1, muscle regeneration
repairinggene therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-ATJC
C-ATJCC-ATJCRNA-binding proteins, AUF1, muscle regeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Regerna Therapeutics RNA-binding proteins, AUF1, muscle regeneration
Regerna Therapeutics is developing regenerative therapeutics to restore functional muscle lost through injury, aging, and dystrophies. Its platform focuses on RNA-binding proteins that regulate RNA stability, splicing, and translation. The company identifies AUF1 as its lead therapeutic and master controller of muscle repair and regeneration, with programs including AUF1 LNP and AAV approaches and REG-A40 for Duchenne Muscular Dystrophy.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Regerna Therapeutics — Early mechanism · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (4 programs at preclinical).…
Source: Deterministic